Novartis Organizes Tokyo Forum For Diabetes Drug Equa
This article was originally published in PharmAsia News
Executive Summary
Following labeling changes that allow longer dosing periods for Novartis AG's Equa (vidagliptin), Japanese physicians reported that the drug's glucose-lowering effect has made the drug a first-choice treatment for type 2 diabetes, said Yukiko Onishi, director of Clinical Trials at Institute for Adult Diseases, Asahi Life Foundation